Randomized trial of carboplatin versus radiotherapy for stage I seminoma Full Text
Journal of Clinical Oncology,  Clinical Article

Oliver RTD et al. – These updated results confirm the noninferiority of single dose carboplatin (at 7 × AUC dose) versus RT in terms of RFR and establish a statistically significant reduction in the medium term of risk of second GCT produced by this treatment.


  • Random assignment was between RT and 1 infusion of carboplatin dosed at 7 × (glomerular filtration rate + 25) on basis of EDTA (n = 357) and 90% of this dose if determined on basis of creatinine clearance (n = 202)
  • Trial powered to exclude doubling in RFRs assuming a 96-97% 2-year RFR after radiotherapy (HR, approximately 2.0)

  • 1,447 patients were randomly assigned in a 3-to-5 ratio (carboplatin, n = 573; RT, n = 904)
  • RFRs at 5 years 94.7% for carboplatin and 96.0% for RT (RT-C 90% CI, 0.7% to 3.5%; HR, 1.25; 90% CI, 0.83 to 1.89)
  • One death as result of seminoma (in RT arm) occurred
  • Patients receiving at least 99% of the 7 × AUC dose had 5-year RFR of 96.1% (95% CI, 93.4% to 97.7%) compared with 92.6% (95% CI, 88.0% to 95.5%) in those who received lower doses (HR, 0.51; 95% CI, 0.24 to 1.07; P = .08)
  • Clear reduction in rate of contralateral GCTs (carboplatin, n = 2; RT, n = 15; HR, 0.22; 95% CI, 0.05 to 0.95; P = .03), and elevated pretreatment FSH levels (> 12 IU/L) was strong predictor (HR, 8.57; 95% CI, 1.82 to 40.38)

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Coffee intake and gastric cancer risk Cancer Epidemiology, Biomarkers & Prevention, March 20, 2014    Clinical Article

2 The dirty side of soap UC San Diego Health System, November 20, 2014

3 Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: The Cancer-DACUS Study Journal of Clinical Oncology, October 10, 2014    Clinical Article

4 Molecular breakthrough could halt the spread of prostate cancer University of Bristol Research News, November 14, 2014

5 Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: A multicentre, open-label, phase 2 trial The Lancet Oncology, November 10, 2014    Clinical Article

6 Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer European Journal of Cancer, August 6, 2014    Clinical Article

7 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 23, 2014    Clinical Article

8 Metformin in chemotherapy-naive castration-resistant prostate cancer: A multicenter phase 2 trial (SAKK 08/09) Full Text European Urology, August 15, 2014    Free full text    Clinical Article

9 New insight on oral cancer culprits Vanderbilt University Medical Center Research News, November 17, 2014

10 Coffee plus honey versus topical steroid in the treatment of chemotherapy-induced oral mucositis: A randomized controlled trial Full Text BMC Complementary and Alternative Medicine, August 28, 2014    Free full text    Clinical Article

11 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 30, 2014    Clinical Article

12 Serum copper is a simple but valuable prognostic marker in B-cell chronic lymphocytic leukemia International Journal of Hematology, October 24, 2014    Clinical Article

13 Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer Journal of Clinical Oncology, November 19, 2014    Clinical Article

14 Phase II trial of the anti-CD19 bispecific T cell–engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia Journal of Clinical Oncology, November 17, 2014    Clinical Article

15 Smoking associated with elevated risk of developing a second smoking-related cancer American Society of Clinical Oncology (ASCO) News, November 12, 2014

16 Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial The Lancet Oncology, October 6, 2014    Clinical Article

17 Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia New England Journal of Medicine, June 4, 2014    Evidence Based Medicine    Clinical Article

18 Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 Annals of Oncology, November 21, 2014    Clinical Article

19 Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer Annals of Oncology, November 4, 2014    Clinical Article

20 Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: A meta-analysis Clinical Cancer Research, November 17, 2014    Evidence Based Medicine

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore